{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T21:33:23Z","timestamp":1790112803761,"version":"4.0.1"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100001454","name":"American Epilepsy Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001454","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001645","name":"Boehringer Ingelheim Fonds","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001645","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.neuropharm.2020.108213","type":"journal-article","created":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T11:13:38Z","timestamp":1593429218000},"page":"108213","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["The adenosine A1 receptor agonist WAG 994 suppresses acute kainic acid-induced status epilepticus in vivo"],"prefix":"10.1016","volume":"176","author":[{"given":"Zin-Juan","family":"Klaft","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina M.","family":"Duerrwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoltan","family":"Gerevich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris G.","family":"Dulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2020.108213_bib1","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jneumeth.2015.08.014","article-title":"In vitro seizure like events and changes in ionic concentration","volume":"260","author":"Antonio","year":"2016","journal-title":"J. Neurosci. Methods"},{"key":"10.1016\/j.neuropharm.2020.108213_bib2","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1007\/s11064-017-2227-7","article-title":"Validation of a preclinical drug screening platform for pharmacoresistant epilepsy","volume":"42","author":"Barker-Haliski","year":"2017","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.neuropharm.2020.108213_bib3","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1161\/01.CIR.94.6.1212","article-title":"Effects of A1 adenosine receptor agonism using N6-cyclohexyl-2'-O-methyladenosine in patients with left ventricular dysfunction","volume":"94","author":"Bertolet","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.neuropharm.2020.108213_bib4","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaneurol.2015.0188","article-title":"Trends in status epilepticus-related hospitalizations and mortality: redefined in US practice over time","volume":"72","author":"Betjemann","year":"2015","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neuropharm.2020.108213_bib5","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S1474-4422(15)00042-3","article-title":"Status epilepticus in adults","volume":"14","author":"Betjemann","year":"2015","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuropharm.2020.108213_bib6","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1535-7597.2004.04110.x","article-title":"Mortality associated with status epilepticus","volume":"4","author":"Boggs","year":"2004","journal-title":"Epilepsy Current"},{"key":"10.1016\/j.neuropharm.2020.108213_bib7","series-title":"Jasper's Basic Mechanisms of the Epilepsies","article-title":"Adenosine augmentation therapy","author":"Boison","year":"2012"},{"key":"10.1016\/j.neuropharm.2020.108213_bib8","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/glia.22285","article-title":"Adenosine dysfunction in epilepsy","volume":"60","author":"Boison","year":"2012","journal-title":"Glia"},{"key":"10.1016\/j.neuropharm.2020.108213_bib9","doi-asserted-by":"crossref","first-page":"3482","DOI":"10.1093\/brain\/awz283","article-title":"Excitatory GABAergic signalling is associated with benzodiazepine resistance in status epilepticus","volume":"142","author":"Burman","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2020.108213_bib10","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0920-1211(01)00187-5","article-title":"Effects of chronic morphine and N(6)-cyclopentyl-adenosine administration on kainic acid-induced status epilepticus","volume":"44","author":"Cano-Martinez","year":"2001","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.neuropharm.2020.108213_bib11","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/nrd3955","article-title":"Adenosine receptors as drug targets--what are the challenges?","volume":"12","author":"Chen","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuropharm.2020.108213_bib12","doi-asserted-by":"crossref","first-page":"160","DOI":"10.2174\/157015909789152146","article-title":"Release of adenosine and ATP during ischemia and epilepsy","volume":"7","author":"Dale","year":"2009","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.neuropharm.2020.108213_bib13","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.neuron.2005.11.009","article-title":"Adenosine and ATP link PCO2 to cortical excitability via pH","volume":"48","author":"Dulla","year":"2005","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2020.108213_bib14","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/j.1528-1157.1980.tb04305.x","article-title":"Endogenously released adenosine regulates excitability in the in vitro hippocampus","volume":"21","author":"Dunwiddie","year":"1980","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2020.108213_bib15","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1476-5381.1980.tb10883.x","article-title":"Adenine nucleotides and synaptic transmission in the in vitro rat hippocampus","volume":"69","author":"Dunwiddie","year":"1980","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108213_bib16","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/ana.410320504","article-title":"Adenosine: a potential mediator of seizure arrest and postictal refractoriness","volume":"32","author":"During","year":"1992","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2020.108213_bib17","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1517\/13543780802497284","article-title":"A1 adenosine receptor agonists and their potential therapeutic applications","volume":"17","author":"Elzein","year":"2008","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.neuropharm.2020.108213_bib18","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1093\/jat\/31.9.581","article-title":"Comparison of drug concentrations in postmortem cerebrospinal fluid and blood specimens","volume":"31","author":"Engelhart","year":"2007","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.neuropharm.2020.108213_bib19","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1093\/brain\/aws091","article-title":"The outcome of therapies in refractory and super-refractory convulsive status epilepticus and recommendations for therapy","volume":"135","author":"Ferlisi","year":"2012","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2020.108213_bib20","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/j.1528-1167.2009.02205.x","article-title":"Treatment of early and late kainic acid-induced status epilepticus with the noncompetitive AMPA receptor antagonist GYKI 52466","volume":"51","author":"Fritsch","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2020.108213_bib21","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1046\/j.1528-1157.2003.03603.x","article-title":"Seizure suppression by adenosine A1 receptor activation in a mouse model of pharmacoresistant epilepsy","volume":"44","author":"Gouder","year":"2003","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2020.108213_bib22","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/epi.12487","article-title":"Purinergic control of hippocampal circuit hyperexcitability in Dravet syndrome","volume":"55","author":"Gu","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2020.108213_bib23","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/j.1528-1167.2011.03337.x","article-title":"Enhanced actions of adenosine in medial entorhinal cortex layer II stellate neurons in temporal lobe epilepsy are mediated via A(1)-receptor activation","volume":"53","author":"Hargus","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2020.108213_bib24","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1212\/WNL.50.3.735","article-title":"Incidence of status epilepticus in Rochester, Minnesota, 1965-1984","volume":"50","author":"Hesdorffer","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2020.108213_bib25","doi-asserted-by":"crossref","first-page":"107904","DOI":"10.1016\/j.neuropharm.2019.107904","article-title":"Role of A1 receptor-activated GIRK channels in the suppression of hippocampal seizure activity","volume":"164","author":"Hill","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2020.108213_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/WNP.0000000000000219","article-title":"Status epilepticus diagnosis, management and outcome: an update","volume":"33","author":"Holtkamp","year":"2016","journal-title":"J. Clin. Neurophysiol."},{"key":"10.1016\/j.neuropharm.2020.108213_bib27","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1136\/jnnp.2004.041947","article-title":"Predictors and prognosis of refractory status epilepticus treated in a neurological intensive care unit","volume":"76","author":"Holtkamp","year":"2005","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.neuropharm.2020.108213_bib28","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3389\/fncel.2019.00124","article-title":"Historical and current adenosine receptor agonists in preclinical and clinical development","volume":"13","author":"Jacobson","year":"2019","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108213_bib29","series-title":"SciPy: Open Source Scientific Tools for Python","author":"Jones","year":"2001"},{"key":"10.1016\/j.neuropharm.2020.108213_bib30","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/epi.13360","article-title":"Adenosine A1 receptor-mediated suppression of carbamazepine-resistant seizure-like events in human neocortical slices","volume":"57","author":"Klaft","year":"2016","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2020.108213_bib31","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1111\/j.1528-1167.2012.03724.x","article-title":"Extracellular ATP differentially affects epileptiform activity via purinergic P2X7 and adenosine A1 receptors in naive and chronic epileptic rats","volume":"53","author":"Klaft","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2020.108213_bib32","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1021\/jm960682u","article-title":"N-substituted adenosines as novel neuroprotective A(1) agonists with diminished hypotensive effects","volume":"42","author":"Knutsen","year":"1999","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2020.108213_bib33","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3389\/fncel.2018.00335","article-title":"Bioenergetic mechanisms of seizure control","volume":"12","author":"Kovacs","year":"2018","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108213_bib34","doi-asserted-by":"crossref","DOI":"10.1523\/ENEURO.0316-17.2017","article-title":"alpha2delta-1 signaling drives cell death, synaptogenesis, circuit reorganization, and gabapentin-mediated neuroprotection in a model of insult-induced cortical malformation","volume":"4","author":"Lau","year":"2017","journal-title":"eNeuro"},{"key":"10.1016\/j.neuropharm.2020.108213_bib35","series-title":"Epidemiology of Status Epilepticus in Adults: Apples, Pears, and Oranges - A Critical Review","author":"Leitinger","year":"2020"},{"key":"10.1016\/j.neuropharm.2020.108213_bib36","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1177\/107424840100600304","article-title":"Electrophysiologic effects of a novel selective adenosine A1 agonist (CVT-510) on atrioventricular nodal conduction in humans","volume":"6","author":"Lerman","year":"2001","journal-title":"J. Cardiovasc. Pharmacol. Therapeut."},{"key":"10.1016\/j.neuropharm.2020.108213_bib37","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jneumeth.2015.03.009","article-title":"Animal models of temporal lobe epilepsy following systemic chemoconvulsant administration","volume":"260","author":"Levesque","year":"2016","journal-title":"J. Neurosci. Methods"},{"key":"10.1016\/j.neuropharm.2020.108213_bib38","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0304-3940(95)12064-B","article-title":"Opposite modulation of 4-aminopyridine and hypoxic hyperexcitability by A1 and A2 adenosine receptor ligands in rat hippocampal slices","volume":"200","author":"Longo","year":"1995","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2020.108213_bib39","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/j.1476-5381.1993.tb13572.x","article-title":"Inhibition by the adenosine analogue, (R-)-N6-phenylisopropyladenosine, of kainic acid neurotoxicity in rat hippocampus after systemic administration","volume":"109","author":"MacGregor","year":"1993","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108213_bib40","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/B978-0-12-801022-8.00011-8","article-title":"Adenosine receptors and epilepsy: current evidence and future potential","volume":"119","author":"Masino","year":"2014","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.neuropharm.2020.108213_bib41","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1172\/JCI57813","article-title":"A ketogenic diet suppresses seizures in mice through adenosine A(1) receptors","volume":"121","author":"Masino","year":"2011","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.neuropharm.2020.108213_bib42","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S1474-4422(07)70074-1","article-title":"Non-convulsive status epilepticus in adults: clinical forms and treatment","volume":"6","author":"Meierkord","year":"2007","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuropharm.2020.108213_bib43","doi-asserted-by":"crossref","first-page":"10166","DOI":"10.1073\/pnas.1810134115","article-title":"Potentiating KCC2 activity is sufficient to limit the onset and severity of seizures","volume":"115","author":"Moore","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2020.108213_bib44","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.eplepsyres.2012.02.012","article-title":"Endogenous adenosine induces NMDA receptor-independent persistent epileptiform discharges in dorsal and ventral hippocampus via activation of A2 receptors","volume":"100","author":"Moschovos","year":"2012","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.neuropharm.2020.108213_bib45","doi-asserted-by":"crossref","first-page":"7724","DOI":"10.1523\/JNEUROSCI.4944-04.2005","article-title":"Trafficking of GABA(A) receptors, loss of inhibition, and a mechanism for pharmacoresistance in status epilepticus","volume":"25","author":"Naylor","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108213_bib46","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1038\/s41380-018-0100-y","article-title":"Diazepam-induced loss of inhibitory synapses mediated by PLCdelta\/Ca(2+)\/calcineurin signalling downstream of GABAA receptors","volume":"23","author":"Nicholson","year":"2018","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2020.108213_bib47","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0031-6989(88)80083-3","article-title":"Antiepileptic effects of N6-L-phenylisopropyladenosine (L-PIA) on penicillin-induced epileptogenic focus in rabbits","volume":"20","author":"Niglio","year":"1988","journal-title":"Pharmacol. Res. Commun."},{"key":"10.1016\/j.neuropharm.2020.108213_bib48","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/534314a","article-title":"Can you teach old drugs new tricks?","volume":"534","author":"Nosengo","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2020.108213_bib49","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1111\/j.1540-8159.1998.tb01201.x","article-title":"Effects of a selective A1-adenosine receptor agonist on heart rate and heart rate variability during permanent atrial fibrillation","volume":"21","author":"Piot","year":"1998","journal-title":"Pacing Clin. Electrophysiol."},{"key":"10.1016\/j.neuropharm.2020.108213_bib50","series-title":"Models of Seizures and Epilepsy","author":"Pitk\u00e4nen","year":"2017"},{"key":"10.1016\/j.neuropharm.2020.108213_bib51","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/j.1528-1167.2006.00504.x","article-title":"Comparison of brain extracellular fluid, brain tissue, cerebrospinal fluid, and serum concentrations of antiepileptic drugs measured intraoperatively in patients with intractable epilepsy","volume":"47","author":"Rambeck","year":"2006","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2020.108213_bib52","doi-asserted-by":"crossref","first-page":"18284","DOI":"10.3390\/ijms140918284","article-title":"Experimental models of status epilepticus and neuronal injury for evaluation of therapeutic interventions","volume":"14","author":"Reddy","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2020.108213_bib53","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.yebeh.2011.07.004","article-title":"Differential neuroprotection by A(1) receptor activation and A(2A) receptor inhibition following pilocarpine-induced status epilepticus","volume":"22","author":"Rosim","year":"2011","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.neuropharm.2020.108213_bib54","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/S1474-4422(11)70187-9","article-title":"Management of refractory status epilepticus in adults: still more questions than answers","volume":"10","author":"Rossetti","year":"2011","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuropharm.2020.108213_bib55","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.neuropharm.2011.09.024","article-title":"Purinergic P2X, P2Y and adenosine receptors differentially modulate hippocampal gamma oscillations","volume":"62","author":"Schulz","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2020.108213_bib56","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1046\/j.1365-2125.1999.00963.x","article-title":"The efficacy of a novel adenosine agonist (WAG 994) in postoperative dental pain","volume":"47","author":"Seymour","year":"1999","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108213_bib57","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/00045391-200405000-00005","article-title":"Pharmacokinetics, pharmacodynamics, and safety of a lipid-lowering adenosine A1 agonist, RPR749, in healthy subjects","volume":"11","author":"Shah","year":"2004","journal-title":"Am. J. Therapeut."},{"key":"10.1016\/j.neuropharm.2020.108213_bib58","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/epi.13270","article-title":"Bumetanide reduces seizure progression and the development of pharmacoresistant status epilepticus","volume":"57","author":"Sivakumaran","year":"2016","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2020.108213_bib59","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1528-1157.1994.tb02908.x","article-title":"Determinants of mortality in status epilepticus","volume":"35","author":"Towne","year":"1994","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2020.108213_bib60","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1111\/epi.13121","article-title":"A definition and classification of status epilepticus--report of the ILAE task force on classification of status epilepticus","volume":"56","author":"Trinka","year":"2015","journal-title":"Epilepsia"},{"issue":"Suppl. 5","key":"10.1016\/j.neuropharm.2020.108213_bib61","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1528-1167.2005.01027.x","article-title":"Modulation of seizures and synaptic plasticity by adenosinergic receptors in an experimental model of temporal lobe epilepsy induced by pilocarpine in rats","volume":"46","author":"Vianna","year":"2005","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2020.108213_bib62","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/0896-6273(94)90321-2","article-title":"Adenosine inhibits evoked synaptic transmission primarily by reducing presynaptic calcium influx in area CA1 of hippocampus","volume":"12","author":"Wu","year":"1994","journal-title":"Neuron"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390820302811?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390820302811?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:05:54Z","timestamp":1758438354000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390820302811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":62,"alternative-id":["S0028390820302811"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2020.108213","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The adenosine A1 receptor agonist WAG 994 suppresses acute kainic acid-induced status epilepticus in vivo","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2020.108213","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108213"}}